Webmd Drugs
Medications and prescription drug information for consumers and medical health professionals. Online database of the most popular drugs and their side effects, interactions, and use.
Webmd Drugs Side Effects
Drugs & Supplements. Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support. Answer your medical questions on prescription drugs, vitamins and Over the Counter medications. Find medical information, terminology and advice including side effects, drug interactions, user.
Xarelto is the brand name for the prescription medication rivaroxaban, a blood thinner, or anticoagulant, that prevents blood clots from forming. Xarelto is in a class of medications called factor Xa inhibitors, which means they affect the action of an enzyme, Factor X, that is involved in blood clotting. Janssen Pharmaceuticals manufactures Xarelto; there is no generic form of rivaroxaban available in the United States.
Xarelto was first approved by the Food and Drug Administration (FDA) in 2011 to (DVT) and prevent (PE) in people having hip or knee replacement surgery. DVT is a condition that develops when a blood clot forms in a vein deep inside the body, usually in the lower leg or thigh. DVT may lead to PE, which is a blood clot in the lung. Also in 2011, the FDA approved Xarelto for people diagnosed with a type of irregular heartbeat called nonvalvular atrial fibrillation (or afib) that is not related to a heart valve problem. Increases a person's risk for blood clots. In 2012, the FDA expanded the approved uses of Xarelto to include prevention of recurring DVT and PE.
If you have one of those conditions you can continue taking the drug to prevent these dangerous blood clots from developing again. Xarelto was tested in a Phase 3 clinical trial for people with recent acute coronary syndrome (ACS); they were given a twice-daily low dose of rivaroxaban as part of their treatment plan. Results of the trial, published in the New England Journal of Medicine, suggested the drug could play an effective role. However, an FDA advisory committee repeatedly voted against expanding Xarelto's uses.